Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio says LentiGlobin is still under EU review, despite conflicting report
→ Closing in on 3 years since Bristol-Myers $BMY struck an option deal to buy Promedior for up to $1.25 billion, the biotech says that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
